In the treatment of advanced prostate cancer (APC) with hormone therapy
Why Wait to Lower Testosterone?
FIRMAGON® (degarelix for injection) the first GnRH receptor antagonist to treat advanced prostate cancer is proven to drop T on day 1.
PRIMARY ENDPOINT: FIRMAGON maintained testosterone suppression below castration level (≤50 ng/dL) over 364 days of treatment.3
BE DIRECT
FIRMAGON, a GnRH antagonist, directly blocks the pituitary GnRH receptors1
FIRMAGON is approved for all stages of APC
FIRMAGON is proven to suppress T in all stages of APC3
Learn MoreMore Than Medicine
Ferring helps you, your patients, and their loved ones throughout their FIRMAGON treatment process.
Abbreviations: GnRH = gonadotropin-releasing hormone; T = testosterone.
REFERENCES: 1. FIRMAGON [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Data on file. Ferring Pharmaceuticals Inc. 3. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.